Medical Imaging

5

min read

Theranostics and Radioligand Therapy: How Imaging Redefines Oncology Trial Endpoints

Theranostics combines a diagnostic imaging agent with a matched radioligand therapy, using the same molecular target to both locate and treat disease. In oncology trials, this pairs imaging directly with treatment, making PET-based response assessment and dosimetry central to endpoint evaluation and often extending beyond conventional RECIST measurement.

In most oncology trials, imaging observes the treatment. It measures what the drug did, from a safe distance, after the fact.

In theranostics the relationship changes. The same molecular target is used to find the disease and to irradiate it, which means the scan is part of the therapeutic decision rather than a report on it. A PET image determines whether the patient is eligible at all. Another quantifies how much radiation the tumor actually received. Imaging stops being the instrument that measures the endpoint and becomes, in part, the intervention.


What Theranostics and Radioligand Therapy Are

Theranostics pairs a diagnostic radiopharmaceutical with a therapeutic one that shares the same targeting molecule. The diagnostic version carries an imaging isotope, typically a positron emitter for PET or a gamma emitter for SPECT. The therapeutic version carries an isotope that delivers cytotoxic radiation, most commonly lutetium-177 or actinium-225.

Radioligand therapy is the therapeutic half of that pair: a targeting ligand chemically bound to a radioactive isotope, administered systemically, which concentrates at cells expressing the target and irradiates them from within. Two target systems dominate current practice. PSMA, prostate-specific membrane antigen, in prostate cancer. And somatostatin receptors, addressed by DOTATATE-based ligands, in neuroendocrine tumors.

The see-and-treat paradigm

The clinical logic is simple and the trial consequences are not. Image first with the diagnostic agent. If the target is expressed at sufficient intensity, treat with the matched therapeutic agent. If it is not, the patient will not benefit and should not be exposed.

The VISION trial of lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer, published by Sartor and colleagues in the New England Journal of Medicine in 2021, is the reference case. PSMA PET imaging was used to identify patients with PSMA-expressing lesions eligible for treatment, and the trial ran with co-primary endpoints of imaging-based progression-free survival and overall survival. Imaging determined who entered the study and imaging determined one of the two answers it produced.

For a sponsor, that means the imaging protocol is no longer downstream of the eligibility criteria. It is the eligibility criteria.


Why Standard Response Criteria Fall Short

RECIST 1.1 measures anatomy. It counts millimeters of tumor diameter and classifies change against fixed thresholds, an approach that works well when a cytotoxic or targeted agent shrinks a lesion. The practical difficulties of applying RECIST consistently are considerable even in that setting, and radioligand therapy adds problems the criteria were not designed for.

Radiation kills cells without necessarily reducing lesion volume on the expected timescale. Fibrotic and necrotic tissue can persist at close to its original size long after it stopped being viable disease. Bone metastases, which dominate in advanced prostate cancer, are frequently non-measurable under RECIST in the first place. And some lesions transiently increase in size or in tracer avidity after treatment, a flare phenomenon that anatomical criteria read as progression.

The result is a mismatch: a therapy whose mechanism is measured in absorbed radiation dose, assessed by criteria built around lesion diameter.


Imaging-Based Endpoints in Radioligand Trials

PET response assessment (PERCIST)

PERCIST, published by Wahl and colleagues in the Journal of Nuclear Medicine in 2009, measures metabolic activity instead of size. Its unit is SUL, the standardized uptake value corrected for lean body mass, measured in a fixed region of interest of roughly 1 cm3 placed in the most metabolically active part of the tumor. Up to five lesions may be followed, with one serving as the primary reference.

Response categories follow the same logic as RECIST but on a different axis. A partial metabolic response requires a decline of at least 30% in SUL peak. Complete metabolic response requires metabolic activity to fall to background level. Progressive metabolic disease is defined by a corresponding increase, or by new metabolically active lesions. Stable metabolic disease is everything in between.

The practical advantage is timing. Metabolic change frequently precedes anatomical change, which matters in a Phase II program where a go or no-go decision arrives before lesions have had time to shrink.

Dosimetry as an endpoint

Dosimetry quantifies the absorbed radiation dose delivered to tumor tissue and to organs at risk, derived from serial imaging after administration. In conventional oncology it has no equivalent. Here it is the closest thing the field has to a direct measure of whether the therapy did what it was designed to do.

It also carries the exposure argument. Kidneys and bone marrow are the dose-limiting organs for most radioligand therapies, and dosimetry is how a program demonstrates that cumulative exposure stayed within acceptable limits across cycles. That makes it simultaneously an efficacy signal and a safety endpoint, which is unusual and operationally demanding: dosimetry requires calibrated acquisition at multiple timepoints, consistent reconstruction parameters and quantitative analysis that is reproducible across sites.


Confirming Best Overall Response

Best overall response is a derived variable, assembled across the whole sequence of timepoints rather than measured at any one of them. In radioligand trials, deriving it correctly is harder than usual for three reasons.

Confirmation requirements have to be specified in advance. A response observed at one timepoint and not confirmed at the next is not a response, and the confirmation window has to account for the delayed kinetics of radiation-induced cell death. Second, when anatomical and metabolic criteria are both collected, the protocol has to state which one governs the primary endpoint and how discordance between them is handled. A lesion that is stable on CT and substantially less avid on PET is a real and common situation, and deciding what it means after the data exists is not defensible.

Third, post-treatment flare has to be anticipated in the response algorithm rather than adjudicated case by case. Without a prespecified rule, the same imaging finding produces different classifications depending on which reader saw it, which is the inter-reader variability problem arriving through the back door.


The Role of the Blinded Independent Central Review (BICR)

Quantitative PET is only comparable across sites if the acquisition is controlled. SUL depends on injected activity, uptake time, patient weight, blood glucose, scanner calibration and reconstruction algorithm. A 20% difference in uptake time between two sites moves the number without anything happening to the tumor. This is the general case for central imaging stated in its most unforgiving form, because a quantitative endpoint has no tolerance for acquisition drift.

A core lab running a theranostic program is therefore responsible for calibration standards across the scanner fleet, fixed uptake windows and acquisition parameters, harmonized reconstruction, blinded independent reading against the criteria the protocol specifies, and dosimetry analysis with documented methodology. The imaging charter has to cover all of it before the first patient is scanned.

Banook works across both halves of this, which is less common than it sounds. The group reads against PERCIST, RECIST 1.1, iRECIST and fifteen other criteria sets, with a panel of more than 500 board-certified specialists worldwide including nuclear medicine physicians and oncologists, each with at least ten years of experience, so reader specialty can be matched to the criteria a protocol actually uses. PET and SPECT sit alongside CT and MRI in the supported modalities. And for radioligand programs specifically, each study carries dedicated dosimetry documentation covering calibration, acquisition requirements and data analysis, in addition to the imaging manual and imaging review charter. Reader consistency is maintained through statistical performance monitoring, consensus sessions, retraining and phantom-based bias checks, across a portfolio of more than 350 imaging studies.


Running a theranostic or radioligand program? Quantitative PET and dosimetry endpoints are decided at protocol stage or not at all. Talk to the Banook imaging team about acquisition standards, criteria selection and dosimetry methodology before the imaging charter is written.


Frequently Asked Questions

What is theranostics?

Theranostics pairs a diagnostic imaging agent with a matched therapeutic agent that shares the same molecular target. The diagnostic version locates disease and confirms target expression; the therapeutic version delivers radiation to the same cells. The approach is used principally in prostate cancer, with PSMA, and in neuroendocrine tumors, with somatostatin receptor ligands.

What is radioligand therapy?

Radioligand therapy is a systemically administered treatment in which a targeting ligand is bound to a radioactive isotope, most often lutetium-177 or actinium-225. The ligand concentrates at cells expressing the target and the isotope irradiates them from within, which allows treatment of disseminated disease that could not be addressed by external beam radiotherapy.

How is response measured in radioligand trials?

Usually through a combination. Anatomical response by RECIST 1.1, metabolic response by PERCIST or a similar PET-based framework, and often absorbed dose by dosimetry. Which one governs the primary endpoint, and how discordance between them is resolved, has to be specified in the protocol rather than decided once the data exists.

What is PET response assessment?

PET response assessment classifies treatment response by change in metabolic activity rather than lesion size. Under PERCIST, the measurement unit is SUL peak in a fixed region of interest of about 1 cm3 in the most metabolically active tumor, and a partial metabolic response requires a decline of at least 30% from baseline.

How does theranostics differ from standard oncology imaging?

In standard oncology, imaging measures the effect of a separate treatment. In theranostics, the imaging agent and the therapeutic agent share a molecular target, so imaging determines eligibility, guides dosing through dosimetry, and measures response. The scan is part of the treatment pathway rather than an observation of it.




Contact us

We would be pleased to answer your questions.

Contact us

Contact us

We would be pleased to answer your questions.

Contact us